Barclays Downgrades Life Tech on Expected NIH Funding Cuts, Portfolio Concerns | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment bank Barclays Capital today downgraded Life Technologies to an Equal Weight rating, citing the company's exposure to an anticipated soft academic and government funding environment and uncertainty about its sequencing portfolio.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.